Latest & greatest articles for gestational diabetes

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on gestational diabetes or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on gestational diabetes and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for gestational diabetes

21. Association of Gestational Diabetes With Maternal Disorders of Glucose Metabolism and Childhood Adiposity. Full Text available with Trip Pro

Association of Gestational Diabetes With Maternal Disorders of Glucose Metabolism and Childhood Adiposity. The sequelae of gestational diabetes (GD) by contemporary criteria that diagnose approximately twice as many women as previously used criteria are unclear.To examine associations of GD with maternal glucose metabolism and childhood adiposity 10 to 14 years' postpartum.The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study established associations of glucose levels during pregnancy (...) with perinatal outcomes and the follow-up study evaluated the long-term outcomes (4697 mothers and 4832 children; study visits occurred between February 13, 2013, and December 13, 2016).Gestational diabetes was defined post hoc using criteria from the International Association of Diabetes and Pregnancy Study Groups consisting of 1 or more of the following 75-g oral glucose tolerance test results (fasting plasma glucose ≥92 mg/dL; 1-hour plasma glucose level ≥180 mg/dL; 2-hour plasma glucose level ≥153 mg/dL

2018 JAMA

22. Gestational Diabetes

Gestational Diabetes © 2002 Kaiser Foundation Health Plan of Washington. All rights reserved. 1 Gestational Diabetes Screening and Treatment Guideline Major Changes as of April 2018 2 Screening Recommendations and Tests 2 Diagnosis 3 Treatment Goals 3 Lifestyle modifications/non-pharmacologic options 3 Pharmacologic options 4 Additional Testing/Monitoring Antenatal monitoring 7 Follow-up after delivery 7 Referral 7 Evidence Summary 8 References 11 Guideline Development Process and Team 12 Last (...) in the guidelines may not be appropriate for use in all circumstances. The inclusion of a recommendation in a guideline does not imply coverage. A decision to adopt any particular recommendation must be made by the provider in light of the circumstances presented by the individual patient. 2 Major Changes as of April 2018 New Previous 2-step gestational diabetes (GDM) screening test 1-step GDM screening test Follow Canadian Diabetes Association blood glucose cutoffs for diagnosis: • Fasting = 95 mg/dL or • 1

2018 Kaiser Permanente Clinical Guidelines

23. Continuation of Atypical Antipsychotic Medication During Early Pregnancy and the Risk of Gestational Diabetes Full Text available with Trip Pro

Continuation of Atypical Antipsychotic Medication During Early Pregnancy and the Risk of Gestational Diabetes Some atypical antipsychotics are associated with metabolic side effects, which are risk factors for gestational diabetes. The authors examined the risk of developing gestational diabetes associated with the continuation of treatment with aripiprazole, ziprasidone, quetiapine, risperidone, and olanzapine during pregnancy compared with discontinuation of these antipsychotic (...) dispensings ("continuers") were compared with women with no dispensings ("discontinuers") during the first half of pregnancy. A generalized linear model and propensity-score stratification were used to obtain absolute and relative risks of developing gestational diabetes, with adjustment for confounders.Women who continued antipsychotic treatment during pregnancy generally had higher comorbidity and longer baseline antipsychotic use. The crude risk of developing gestational diabetes among continuers

2018 EvidenceUpdates

24. Gestational diabetes

Gestational diabetes Top results for gestational diabetes - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look (...) like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for gestational diabetes The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials

2018 Trip Latest and Greatest

25. Continuous glucose monitoring results in lower HbA1c in Malaysian women with insulin-treated gestational diabetes: a randomized controlled trial Full Text available with Trip Pro

Continuous glucose monitoring results in lower HbA1c in Malaysian women with insulin-treated gestational diabetes: a randomized controlled trial To determine if therapeutic, retrospective continuous glucose monitoring (CGM) improves HbA1c with less hypoglycaemia in women with insulin-treated gestational diabetes mellitus (GDM).This prospective, randomized controlled, open-label trial evaluated 50 women with insulin-treated GDM randomized to either retrospective CGM (6-day sensor) at 28, 32 (...) and 36 weeks' gestation (Group 1, CGM, n = 25) or usual antenatal care without CGM (Group 2, control, n = 25). All women performed seven-point capillary blood glucose (CBG) profiles at least 3 days per week and recorded hypoglycaemic events (symptomatic and asymptomatic CBG < 3.5 mmol/l; non-fasting < 4.0 mmol/l). HbA1c was measured at 28, 33 and 37 weeks. In Group 1, both CGM and CBG data were used to manage diabetes, whereas mothers in Group 2 were managed based on CBG data alone.Baseline

2018 EvidenceUpdates

26. Gestational diabetes

Gestational diabetes Evidence Maps - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4

2018 Trip Evidence Maps

27. Safety of non-insulin glucose-lowering drugs in pregnant women with pre-gestational diabetes: A cohort study (Abstract)

Safety of non-insulin glucose-lowering drugs in pregnant women with pre-gestational diabetes: A cohort study To evaluate the association between use of non-insulin antidiabetics in early pregnancy and the risk of miscarriages, stillbirths and major structural malformations.A cohort of 1511 pregnant women with pre-gestational diabetes linked to live births was identified using electronic medical records from The Health Improvement Network (THIN) for the period 1995 to 2012. Information (...) on prescriptions, foetal outcomes and potential confounders was ascertained from both codes and free text in the THIN database. Odds ratios (OR) and 95% confidence intervals (CI) of adverse foetal outcomes in women treated with non-insulin antidiabetics during the first trimester compared to those on insulin were estimated using logistic regression to adjust for type of diabetes, glycaemic control and other maternal characteristics.Among 311 pregnant women on non-insulin antidiabetics, 21.9% had a miscarriage

2018 EvidenceUpdates

28. A Tailored Letter Based on Electronic Health Record Data Improves Gestational Weight Gain Among Women With Gestational Diabetes: The Gestational Diabetes` Effects on Moms (GEM) Cluster-Randomized Controlled Trial Full Text available with Trip Pro

A Tailored Letter Based on Electronic Health Record Data Improves Gestational Weight Gain Among Women With Gestational Diabetes: The Gestational Diabetes` Effects on Moms (GEM) Cluster-Randomized Controlled Trial Evaluate whether a tailored letter improved gestational weight gain (GWG) and whether GWG mediated a multicomponent intervention's effect on postpartum weight retention among women with gestational diabetes mellitus (GDM).A cluster-randomized controlled trial of 44 medical facilities (...) postpartum weight retention.© 2018 by the American Diabetes Association.

2018 EvidenceUpdates

29. Effect of Glyburide vs Subcutaneous Insulin on Perinatal Complications Among Women With Gestational Diabetes: A Randomized Clinical Trial. Full Text available with Trip Pro

Effect of Glyburide vs Subcutaneous Insulin on Perinatal Complications Among Women With Gestational Diabetes: A Randomized Clinical Trial. Randomized trials have not focused on neonatal complications of glyburide for women with gestational diabetes.To compare oral glyburide vs subcutaneous insulin in prevention of perinatal complications in newborns of women with gestational diabetes.The Insulin Daonil trial (INDAO), a multicenter noninferiority randomized trial conducted between May 2012 (...) and November 2016 (end of participant follow-up) in 13 tertiary care university hospitals in France including 914 women with singleton pregnancies and gestational diabetes diagnosed between 24 and 34 weeks of gestation.Women who required pharmacologic treatment after 10 days of dietary intervention were randomly assigned to receive glyburide (n=460) or insulin (n=454). The starting dosage for glyburide was 2.5 mg orally once per day and could be increased if necessary 4 days later by 2.5 mg and thereafter

2018 JAMA Controlled trial quality: predicted high

30. Gestational Diabetes Mellitus

Gestational Diabetes Mellitus Sign In (ACOG) Sign in to your ACOG account Email is required. Please enter valid Email. was not found in our system. Would you like to associated with your account? Forgot your email address? JSOG Member? © 2019 - American College of Obstetricians and Gynecologists

2018 American College of Obstetricians and Gynecologists

31. The impact of a daily smartphone-based feedback system among women with gestational diabetes on compliance, glycemic control, satisfaction, and pregnancy outcome: a randomized controlled trial Full Text available with Trip Pro

The impact of a daily smartphone-based feedback system among women with gestational diabetes on compliance, glycemic control, satisfaction, and pregnancy outcome: a randomized controlled trial Patient compliance and tight glycemic control have been demonstrated to improve outcome in pregnancies complicated by gestational diabetes mellitus. The use of advanced technological tools, including smartphone-based platforms, to improve medical care and outcomes has been demonstrated in various fields (...) of medicine, but only a few small studies were performed with gestational diabetes mellitus patients.We aimed to study the impact of introducing a smartphone-based daily feedback and communication platform between gestational diabetes mellitus patients and their physicians, on patient compliance, glycemic control, pregnancy outcome, and patient satisfaction.This is a prospective, single-center, randomized controlled trial. Newly diagnosed gestational diabetes mellitus patients presenting to our

2018 EvidenceUpdates

32. A systematic review and meta-analysis of the association between vitamin D deficiency and gestational diabetes mellitus Full Text available with Trip Pro

A systematic review and meta-analysis of the association between vitamin D deficiency and gestational diabetes mellitus A systematic review and meta-analysis of the association between vitamin D deficiency and gestational diabetes mellitus | Biomedical Research and Therapy Menu The Vietnamese Journal of Biomedicine / 2078-2095 A systematic review and meta-analysis of the association between vitamin D deficiency and gestational diabetes mellitus Shahin Nargesi × Department of Public Health (...) ., Mohamadpour, M., Mousavi, S., & Amraei, M. (2018). A systematic review and meta-analysis of the association between vitamin D deficiency and gestational diabetes mellitus. Biomedical Research and Therapy , 5 (3), 2078-2095. https://doi.org/10.15419/bmrat.v5i3.422 Copyrights: Shahin Nargesi, Ayub Ghorbani, Ehsan Shirzadpour, Mahmoud Mohamadpour, Seyedeh Fatemeh Mousavi, Mansour Amraei, 2018. License: This work is licensed under a . Abstract Introduction : Vitamin D deficiency has become quite prevalent

2018 Biomedical Research and Therapy

33. Planned birth at or near term for improving health outcomes for pregnant women with gestational diabetes and their infants. Full Text available with Trip Pro

Planned birth at or near term for improving health outcomes for pregnant women with gestational diabetes and their infants. Gestational diabetes is a type of diabetes that occurs during pregnancy. Women with gestational diabetes are more likely to experience adverse health outcomes such as pre-eclampsia or polyhydramnios (excess amniotic fluid). Their babies are also more likely to have health complications such as macrosomia (birthweight > 4000 g) and being large-for-gestational age (...) (birthweight above the 90th percentile for gestational age). Current clinical guidelines support elective birth, at or near term in women with gestational diabetes to minimise perinatal complications, especially those related to macrosomia.This review replaces a review previously published in 2001 that included "diabetic pregnant women", which has now been split into two reviews. This current review focuses on pregnant women with gestational diabetes and a sister review focuses on women with pre-existing

2018 Cochrane

34. Gestational diabetes mellitus — an update on screening, diagnosis, and follow-up

Gestational diabetes mellitus — an update on screening, diagnosis, and follow-up '); } else { document.write(' '); } ACE | Gestational diabetes mellitus — an update on screening, diagnosis, and follow-up Search > > Gestational diabetes mellitus — an update on screening, diagnosis, and follow-up - Gestational diabetes mellitus — an update on screening, diagnosis, and follow-up Published on 28 May 2018 This Appropriate Care Guide (ACG) features new recommendations for screening and diagnosing (...) gestational diabetes mellitus. It highlights the shift from risk-based to universal screening for all women at 24 to 28 weeks of gestation, and WHO 1999 to IADPSG 2010 glucose thresholds for GDM. It also highlights the importance of long-term care for women with GDM history. Download the PDF below to access the full ACG. Key Messages 1. During their first trimester, screen high-risk women for pre-existing diabetes using non-pregnancy glucose thresholds. If results are normal, re-evaluate women for GDM

2018 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

35. Post-Partum Screening and Monitoring for Gestational Diabetes: Clinical Effectiveness and Guidelines

Post-Partum Screening and Monitoring for Gestational Diabetes: Clinical Effectiveness and Guidelines Post-Partum Screening and Monitoring for Gestational Diabetes: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Post-Partum Screening and Monitoring for Gestational Diabetes: Clinical Effectiveness and Guidelines Post-Partum Screening and Monitoring for Gestational Diabetes: Clinical Effectiveness and Guidelines Last updated: August 28, 2018 Project Number: RB1251 (...) -000 Product Line: Research Type: Other Diagnostics Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of an intervention to screen and monitor patients post-partum gestational diabetes? What are the evidence-based guidelines regarding post-partum gestational diabetes screening or monitoring? Key Message Three systematic reviews, two randomized controlled trials, six non-randomized studies, and four evidence-based guidelines were identified regarding

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

36. SMFM Statement Pharmacological treatment of gestational diabetes Full Text available with Trip Pro

SMFM Statement Pharmacological treatment of gestational diabetes SMFM Statement: Pharmacological treatment of gestational diabetes - American Journal of Obstetrics & Gynecology Email/Username: Password: Remember me Search Terms Search within Search Share this page: Access provided by Volume 218, Issue 5, Pages B2–B4 SMFM Statement: Pharmacological treatment of gestational diabetes Society of Maternal-Fetal Medicine (SMFM) Publications Committee ∗ Society for Maternal-Fetal Medicine, Washington (...) , DC DOI: | Publication History Published online: February 03, 2018 Expand all Collapse all Treatment for gestational diabetes mellitus (GDM) is associated with improved perinatal outcomes that include reduced frequency of hypertensive disorders of pregnancy, delivery of a large-for-gestational-age (LGA) infant, shoulder dystocia, and cesarean delivery. x 1 Landon, M.B., Spong, C.Y., Thom, E. et al. A multicenter, randomized trial of treatment for mild gestational diabetes. N Engl J Med . 2009

2018 Society for Maternal-Fetal Medicine

37. Gestational diabetes mellitus

Gestational diabetes mellitus Gestational diabetes mellitus - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Gestational diabetes mellitus Last reviewed: February 2019 Last updated: April 2018 Summary Develops during pregnancy and is usually diagnosed at 24 to 28 weeks of gestation on the basis of elevated plasma glucose levels on glucose tolerance testing. Goal of therapy is to achieve maternal glucose levels (...) that are as close to normal as possible in order to avoid fetal macrosomia and complications. Initial therapy for gestational diabetes is usually dietary modification. Insulin is started when acceptable glucose levels cannot be maintained with diet alone. Maternal postnatal testing for diabetes or impaired glucose tolerance is performed at least 6 weeks following delivery. The risk for recurrence of GDM in subsequent pregnancies or progression to type 2 diabetes is high. Definition Gestational diabetes mellitus

2018 BMJ Best Practice

38. Comparison of umbilical artery Doppler and non-stress test in assessment of fetal well-being in gestational diabetes mellitus: A prospective cohort study Full Text available with Trip Pro

Comparison of umbilical artery Doppler and non-stress test in assessment of fetal well-being in gestational diabetes mellitus: A prospective cohort study Gestational diabetes mellitus (GDM) is one of the most common medical complications of pregnancy and is related to poor perinatal outcomes. Reduction of neonatal complications of GDM is feasible by assessment of fetal well-being. Both fetal Doppler and NST are used for the screening of high-risk pregnancies.We aimed to compare the non-stress (...) test (NST) and umbilical artery (UA) Doppler assessments for evaluation of the adverse perinatal outcomes in GDM.We conducted a prospective cohort study on 50 pregnant women with GDM in Jame Zanan Hospital, Tehran, Iran, from Oct 2014 to Sep 2015. A convenient sampling method was used for patient recruitment. Inclusion criteria were women with GDM, singleton pregnancies, and gestational age>32 weeks who had neither medical conditions nor fetal anomalies. Adverse perinatal outcomes were defined

2017 Electronic physician

39. miR-494 protects pancreatic β-cell function by targeting PTEN in gestational diabetes mellitus Full Text available with Trip Pro

miR-494 protects pancreatic β-cell function by targeting PTEN in gestational diabetes mellitus Gestational diabetes mellitus (GDM) is one of the most common pregnancy complications characterized by insulin resistance and pancreatic β-cell dysfunction. Increasing evidence suggests that microRNAs (miRNAs) play key roles in the diverse types of diabetes, including GDM. However, the underlying mechanisms remain largely unknown. The purpose of this study is to investigate the role of microRNAs (...) in GDM. The microarray data of dysregulated miRNAs in blood and placenta was retrieved in the GEO dataset under the accession number GSE19649. Quantitative reverse transcription PCR (qRT-PCR) was performed to analyze the expression levels of miR-494 in peripheral blood from twenty pairs of gestational diabetes (GDM) women and healthy women. Then, we investigated the effects of miR-494 on the insulin secretion of pancreatic β-cells. Moreover, the role of this miR-494 in regulating the proliferation

2017 EXCLI journal

40. Health app: GDm-Health for people with gestational diabetes

Health app: GDm-Health for people with gestational diabetes Health app: GDm-Health for people with Health app: GDm-Health for people with gestational diabetes gestational diabetes Medtech innovation briefing Published: 13 November 2017 nice.org.uk/guidance/mib131 pathways Summary Summary About this app GDm-Health is a health application designed for people with gestational diabetes to allow for remote monitoring of blood glucose levels and communication with healthcare professionals. The mobile (...) a positive impact for people with gestational diabetes. There is some evidence that the app is a reliable method to communicate blood glucose levels and improves patient satisfaction with their care. However, there is currently no evidence comparing GDm-Health with standard care and so the impact on clinical outcomes is uncertain. Cost and resource impact Cost and resource impact: Cost savings may arise from reducing the need for face-to-face appointments but the overall resource impact has not been

2017 National Institute for Health and Clinical Excellence - Advice